Preview

Научно-практическая ревматология

Расширенный поиск

Ревматоидный артрит и венозные тромбоэмболические осложнения

https://doi.org/10.14412/1995-4484-2016-456-462

Полный текст:

Аннотация

В обзоре литературы приводятся данные последних исследований, в которых было продемонстрировано, что ревматоидный артрит увеличивает частоту развития венозных тромбоэмболических осложнений. Рассматриваются патогенез тромбоза при воспалительных хронических заболеваниях, связь воспалительного процесса и тромбообразования. Обсуждается вопрос влияния лекарственных препаратов, применяемых у больных ревматоидным артритом, на риск тромбообразования. 

Об авторе

М. А. Сатыбалдыева
ФГБНУ Научно-исследовательский институт ревматологии им. В.А. Насоновой, Москва
Россия

младший научный сотрудник лаборатории системных ревматических заболеваний с группой гемореологических нарушений

115522 Москва, Каширское шоссе, 34А 



Список литературы

1. Heit JA, Silverstein MD, Mohr DN, et al. The epidemiology of venous thromboembolism in the community. Thromb Haemost. 2001;86:452-63. doi: 10.1161/ATVBAHA.108.162545

2. Савельев ВС, Чазов ЕИ, Гусев ИЕ и др. Российские клинические рекомендации по диагностике, лечению и профилактике венозных тромбоэмболических осложнений. Флебология. 2010;4(2):1-37 [Savel'ev VS, Chazov EI, Gusev IE, et al. Russian clinical recommendations for diagnosis, treatment and prevention of venous thromboembolic events. Flebologiya. 2010;4(2):1-37 (In Russ.)].

3. Zö ller B, Li X, Sundquist J, et al. Autoimmune diseases and venous thromboembolism: a review of the literature. Am J Cardiovasc Dis. 2012;2(3):171-83. Epub 2012 Jul 25.

4. Lijfering WM, Rosendaal FR, Cannegieter SC. Risk factors for venous thrombosis – current understanding from an epidemiological point of view. Br J Haematol. 2010 Jun;149(6):824-33. doi: 10.1111/j.1365-2141.2010.08206.x. Epub 2010 Apr 29.

5. Пизова НВ. Тромбофилии: генетические полиморфизмы и сосудистые катастрофы. Москва: ИМА-ПРЕСС; 2013. 248 с. [Pizova NV. Trombofilii: geneticheskie polimorfizmy i sosudistye katastrofy [Thrombophilia: genetic polymorphisms, and cardiovascular accident]. Moscow: IMA-PRESS; 2013. 248 p.].

6. Bezemer ID, van der Meer FJ, Eikenboom JC, et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med. 2009;169:610-5. doi: 10.1001/archinternmed.2008.589

7. Решетняк ТМ, Щербакова МЮ, Жданова ЛВ и др. Антифосфолипидный синдром, антифосфолипидные антитела и генетические тромбофилии у детей с соматической патологией. Научно-практическая ревматология. 2008;46(4):48-57 [Reshetnyak TM, Sherbakova MY, Zdanova LV, Nasonov EL. Antiphospholipid syndrome, antiphospholipid antibodies and genetic thrombophilias in children TOC with somatic pathology. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2008;46(4):48-57 (In Russ.)]. doi: 10.14412/1995-4484-2008-536

8. Решетняк ТМ. Антифосфолипидный синдром: диагностика и клинические проявления (лекция). Научно-практическая ревматология. 2014;52(1):56-71 [Reshetnyak TM. Antiphospholipid syndrome: diagnosis and clinical manifestations (a lecture). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2014;52(1):56-71 (In Russ.)]. doi: 10.14412/1995-4484-2014-56-71

9. Xu J, Lupu F, Esmon CT. Inflammation, innate immunity and blood coagulation. Hamostaseologie. 2010;30(5-6):8-9.

10. Dahlback B. Coagulation and inflammation-close allies in health and disease. Semin Immunopathol. 2012;34:1-3. doi: 10.1007/s00281-011-0298-0. Epub 2011 Nov 5.

11. Hoppe B, Dö rner T. Coagulation and the fibrin network in rheumatic disease: a role beyond haemostasis. Nat Rev Rheumatol. 2012 Dec;8(12):738-46. doi: 10.1038/nrrheum.2012.184. Epub 2012 Nov 13.

12. Harris ED Jr. Rheumatoid arthritis: pathophysiology band implications for therapy. N Engl J Med. 1990;322:1277-89. doi: 10.1056/NEJM199005033221805

13. Насонов ЕЛ, Каратеев ДЕ, Балабанова РМ. Ревматоидный артрит. В кн.: Насонов ЕЛ, Насонова ВА, редакторы. Ревматология. Национальное руководство. Москва: ГЭОТАР-Медиа; 2008. С. 290-331 [Nasonov EL, Karateev DE, Balabanova RM. Rheumatoid arthritis. In: Nasonov EL, Nasonova VA, editors. Revmatologiya. Natsional’noe rukovodstvo [Rheumatology. National guidelines]. Moscow: GEOTAR-Media; 2008. P. 290-331].

14. Loof TG, Schmidt O, Herwald H, et al. Coagulation systems of invertebrates and vertebrates and their roles in innate immunity: the same side of two coins? J Innate Immun. 2011;3(1):34-40. doi: 10.1159/000321641. Epub 2010 Nov 3.

15. Esmon CT, Esmon NL. The link between vascular features and thrombosis. Annu Rev Physiol. 2011;73:503-14. doi: 10.1146/annurev-physiol-012110-142300

16. Струкова СМ. Основы физиологии гемостаза. Учебное пособие. 2-е изд. Москва: Издательство МГУ; 2013. С. 148-84 [Strukova SM. Osnovy fiziologii gemostaza. Uchebnoe posobie [Fundamentals of physiology of hemostasis. Tutorial]. 2nd ed. Moscow: Publishing house of the Moscow State University; 2013. P. 148-84].

17. Esmon CT. The interactions between inflammation and coagulation. Br J Haematol. 2005;131:417-30. doi: 10.1111/j.1365- 2141.2005.05753.x

18. Cirillo P, Golin P, Calabro P, et al. C-reactive protein induces tissue factor expression and promotes smooth muscle and endothelial cell proliferation. Cardiovasc Res. 2005;68:47-55. doi: 10.1016/j.cardiores.2005.05.010

19. Santos MJ, Carmona-Fernandes D, Canhao H, et al. Early vascular alterations in SLE and RA patients – a step towards understanding the associated cardiovascular risk. PLoS One 2012;7:e44668. doi: 10.1371/journal.pone.0044668. Epub 2012 Sep 4.

20. McEntegart A, Capell HA, Creran D, et al. Cardiovascular risk factors, including thrombotic variables, in a population with rheumatoid arthritis. Rheumatology (Oxford). 2001;40:640-4. doi: 10.1093/rheumatology/40.6.640

21. McLaren M, Alkaabi J, Connacher M, et al. Activated factor XII in rheumatoid arthritis. Rheumatol Int. 2002 Sep;22(5):182-4. doi: 10.1007/s00296-002-0219-6. Epub 2002 Aug 9.

22. Peters MJ, Nurmohamed MT, van Eijk IC, et al. Thrombin-activatable fibrinolysis inhibitor and its relation with inflammation in rheumatoid arthritis. Ann Rheum Dis. 2009;68:1232-3. doi: 10.1136/ard.2008.097485

23. Rooney T, Scherzer R, Shigenaga JK, et al. Levels of plasma fib￾rinogen are elevated in well-controlled rheumatoid arthritis. Rheumatology (Oxford). 2011;50:1458-65. doi: 10.1093/rheumatology/ker011. Epub 2011 Mar 26.

24. Wallberg-Jonsson S, Dahlen GH, Nilsson TK, et al. Tissue plasminogen activator, plasminogen activator inhibitor-1 and von Willebrand factor in rheumatoid arthritis. Clin Rheumatol. 1993;12:318-24. doi: 10.1007/BF02231572

25. Van der Poll T, Levi M, Buller HR, et al. Fibrinolytic response to tumor necrosis factor in healthy subjects. J Exp Med. 1991;174:729-32. doi: 10.1084/jem.174.3.729

26. Esmon CT. Coagulation inhibitors in inflammation. Biochem Soc Trans. 2005;33:401-5. doi: 10.1042/BST0330401

27. Ardon SP, Shanahan JC, Pisetsky DS. The role of microparticles in inflammation and thrombosis. Scand J Immunol. 2007;66:159- 65. doi: 10.1111/j.1365-3083.2007.01984.x

28. Esmon CT. Protein C anticoagulant system – anti-inflammatory effects. Semin Immunopathol. 2012;34:127-32. doi: 10.1007/s00281-011-0284-6. Epub 2011 Aug 6.

29. Matta F, Singala R, Yaekoub AY, et al. Risk of venous thromboembolism with rheumatoid arthritis. Thromb Haemost. 2009 Jan;101(1):134-8. doi: 10.1160/TH08-08-0551

30. Ramagopalan SV, Wotton CJ, Handel AE, et al. Risk of venous thromboembolism in people admitted to hospital with selected immune-mediated diseases record-linkage study. BMC Med. 2011;9:1-8. doi: 10.1186/1741-7015-9-1

31. Zoller B, Li X, Sundquist K. Risk of pulmonary embolism in patients with autoimmune disorders a nationwide follow-up study from Sweden. Lancet. 2012;379:244-9. doi: 10.1016/S0140- 6736(11)61306-8. Epub 2011 Nov 25.

32. Johannesdottir SA, Schmidt M, Horvath-Puho E, et al. Autoimmune skin and connective tissue diseases and risk of venous thromboembolism a population-based case-control study. J Thromb Haemost. 2012;10:815-21. doi: 10.1111/j.1538- 7836.2012.04666.x

33. Liang KP, Liang KV, Matteson EL, et al. Incidence of noncardiac vascular disease in rheumatoid arthritis and relationship to extraarticular disease manifestations. Arthritis Rheum. 2006;54(2):642-8. doi: 10.1002/art.21628

34. Алекберова ЗС, Герасимова ЕВ, Голоева РГ, Насонов ЕЛ. Тромбозы и ревматические заболевания: частота встречаемости и механизмы развития (обзор и собственные данные). Научно-практическая ревматология. 2012;50(1):65- 71 [Alekberova ZS, Gerasimova EV, Goloeva RG, Nasonov EL. Thrombosis and rheumatic disease: frequency of occurrence and development mechanisms (review and own data). Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2012;50(1):65-71 (In Russ.)]. doi: 10.14412/1995-4484- 2012-507

35. Wei-Sheng Chung, Chiao-Ling Peng, Cheng-Li Lin, et al. Rheumatoid arthritis increases the risk of deep vein thrombosis and pulmonary thromboembolism: a nationwide cohort study. Ann Rheum Dis. 2014;73:1774-80. doi: 10.1136/annrheumdis-2013- 203380. Epub 2013 Aug 7.

36. Kim SC, Schneeweiss S, Liu J, et al. The risk of venous thromboembolism in patients with rheumatoid arthritis. Arthritis Care Res (Hoboken). 2013 Oct;65(10):1600-7. doi: 10.1002/acr.22039

37. Ungprasert P, Srivali N, Spanuchart I, et al. Risk of venous thromboembolism in patients with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol. 2014 Mar;33(3):297-304. doi: 10.1007/s10067-014-2492-7. Epub 2014 Jan 15.

38. Abernethy PJ. Surgery of the rheumatoid knee. Ann Rheum Dis. 1990;49(2):830-6. doi: 10.1136/ard.49.Suppl_2.830

39. Van Heereveld HA, Laan RF, van den Hoogen FH, et al. Prevention of symptomatic thrombosis with short term (low molecular weight) heparin in patients with rheumatoid arthritis after hip or knee replacement. Ann Rheum Dis. 2001;60(10):974-6. doi: 10.1136/ard.60.10.974

40. McLaughlin GE. Sudden death in rheumatoid arthritis: pulmonary embolism – a fatal complication of iliopsoas bursitis. J Clin Rheumatol. 2002 Aug;8(4):208-11. doi: 10.1097/00124743- 200208000-00007

41. Govedarski V, Denchev B, Nedevska M, et al. Vascular complications of Baker’s cyst. Khirurgiia (Sofiia). 2007;(4):65-7.

42. Palareti G, Cosmi B, Legnani C, et al. D-dimer testing to determine the duration of anticoagulation therapy. N Engl J Med. 2006;355:1780-9. doi: 10.1016/j.jvs.2006.11.010

43. Brotman DJ, Girod JP, Posch A, et al. Effects of short-term glucocorticoids on hemostatic factors in healthy volunteers. Thromb Res. 2006;118(2):247-52. doi: 10.1016/j.thromres.2005.06.006

44. Сатыбалдыев АМ. Глюкокортикоидный синдром Кушинга в практике ревматолога (обзор литературы). Современная ревматология. 2013;7(4):78-84 [Satybaldyev AM. Cushing’s glucocorticoid syndrome in the practice of a rheumatologist (A review of literature). Sovremennaya Revmatologiya = Modern Rheumatology Journal. 2013;7(4):78-84. (In Russ.)]. doi: 10.14412/1996-7012-2013-2443

45. Biere-Rafi S, Di Nisio M, Gerdes V, et al. Non-steroidal antiinflammatory drugs and risk of pulmonary embolism. Pharmacoepidemiol Drug Saf. 2011 Jun;20(6):635-42. doi: 10.1002/pds.2130

46. Schmidt M, Christiansen CF, Horvath-Puho E, et al. Nonsteroidal anti-inflammatory drug use and risk of venous thromboembolism. J Thromb Haemost. 2011 Jul;9(7):1326-33. doi: 10.1111/j.1538-7836.2011.04354.x

47. Tsai AW, Cushman M, Rosamond WD, et al. Cardiovascular risk factors and venous thromboembolism incidence: the longitudinal investigation of thromboembolism etiology. Arch Intern Med. 2002 May 27;162(10):1182-9. doi: 10.1001/archinte.162.10.1182

48. Lacut K, van der Maaten J, Le Gal G, et al. Antiplatelet drugs and risk of venous thromboembolism: results from the EDITH casecontrol study. Haematologica. 2008 Jul;93(7):1117-8. doi: 10.3324/haematol.12331

49. Landewe RB, van den Borne B, Breedveld FC, et al. Methotrexate effects in patients with rheumathoid arthritis with cardiovascular comorbidity. Lancet. 2000;355:1616-7. doi: 10.1016/S0140- 6736(00)02222-4

50. Кириенко АИ, Панченко ЕП, Андрияшкин ВВ. Венозный тромбоз в практике терапевта и хирурга. Москва: Планида; 2012. C. 18-9 [Kirienko AI, Panchenko EP, Andriyashkin VV. Venoznyi tromboz v praktike terapevta i khirurga [Venous thrombosis in the practice of physician and surgeon]. Moscow: Planida; 2012. P. 18-9].

51. Широкова ИЕ, Решетняк ТМ. Гипергомоцистеинемия – дополнительный фактор риска тромбозов при системной красной волчанке и антифосфолипидном синдроме. Научно- практическая ревматология. 2003;41(4):39-43 [Shirokova IE, Reshelnyak TM. Hyperhomocysteinemia – an additional risk factor of thrombosis in systemic lupus erythematosus and antiphospholipid syndrome. Nauchno-Prakticheskaya Revmatologiya = Rheumatology Science and Practice. 2003;41(4):39-43 (In Russ.)]. doi: 10.14412/1995-4484-2003-1331

52. Korswagen LA, Bartelds GM, Krieckaert CL, et al. Venous and arterial thromboembolic events in adalimumab-treated patients with antiadalimumab antibodies: a case series and cohort study. Arthritis Rheum. 2011 Apr;63(4):877-83. doi: 10.1002/art.30209

53. Petitpain N, Gambier N, Wahl D, et al. Arterial and venous thromboembolic events during anti-TNF therapy: a study of 85 spontaneous reports in the period 2000-2006. Biomed Mater Eng. 2009;19(4-5):355-64. doi: 10.3233/BME-2009-0600

54. Davies R, Galloway JB, Watson KD, et al. Venous thrombotic events are not increased in patients with rheumatoid arthritis treated with anti-TNF therapy: results from the British Society for Rheumatology Biologics Register. Ann Rheum Dis. 2011 Oct;70(10):1831-4. doi: 10.1136/ard.2011.153536. Epub 2011 Jul 22.

55. Ingegnoli F, Fantini F, Griffini S, et al. Anti-tumor necrosis factor alpha therapy normalizes fibrinolysis impairment in patients with active rheumatoid arthritis. Clin Exp Rheumatol. 2010 Mar-Apr;28(2):254-7. Epub 2010 May 13.

56. Ferraro-Peyret C, Coury F, Tebib JG, et al. Infliximab therapy in rheumatoid arthritis and ankylosing spondylitis-induced specific antinuclear and antiphospholipid autoantibodies without autoimmune clinical manifestations: a two-year prospective study. Arthritis Res Ther. 2004;6(6):R535-43. doi: 10.1186/ar1440. Epub 2004 Sep 23.

57. Virupannavar S, Brandau A, Guggenheim C, et al. Possible association of etanercept, venous thrombosis, and induction of antiphospholipid syndrome. Case Rep Rheumatol. 2014;2014:801072. doi: 10.1155/2014/801072. Epub 2014 May 15.

58. Jonsdottir Т, Forslid J, van Vollenhoven A, et al. Treatment with tumour necrosis factor α antagonists in patients with rheumatoid arthritis induces anticardiolipin antibodies. Ann Rheum Dis. 2004;63:1075-8. doi: 10.1136/ard.2003.018093. Epub 2004 Apr 5.

59. Makol A, Grover M, Guggenheim C, et al. Etanercept and venous thromboembolism: a case series. J Med Case Rep. 2010 Jan 15;4:12. doi: 10.1186/1752-1947-4-12


Для цитирования:


Сатыбалдыева М.А. Ревматоидный артрит и венозные тромбоэмболические осложнения. Научно-практическая ревматология. 2016;54(4):456-462. https://doi.org/10.14412/1995-4484-2016-456-462

For citation:


Satybaldyeva M.A. Rheumatoid arthritis and venous thromboembolic events. Rheumatology Science and Practice. 2016;54(4):456-462. (In Russ.) https://doi.org/10.14412/1995-4484-2016-456-462

Просмотров: 295


Creative Commons License
Контент доступен под лицензией Creative Commons Attribution 4.0 License.


ISSN 1995-4484 (Print)
ISSN 1995-4492 (Online)